No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
210 (estimated)
Sponsor
First Ascent Biomedical Inc. · Industry
Who this trial is looking for
This trial is looking for cancer patients in Florida, particularly those who are underserved. Participants will use a new platform to help their doctors understand their treatment options better.
Are You a Good Fit for This Trial?
You may be able to join if
I have recurrent or refractory cancer and am up to 18 years old.
I have recurrent or refractory cancer and am 18 years or older.
I have received at least one prior standard treatment.
I can provide information about my previous treatments.
I am healthy enough to undergo cancer therapy.
I am scheduled for or have recently had a tumor biopsy or surgery.
I am willing to provide a blood sample or buccal swab for testing.
You may not be able to join if
I do not have enough malignant tissue available for testing.
I don't have enough information to assess my health status.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next l…
Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Patients with recurrent/refractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)
* -OR- Patients with recurrent/refractory cancer ≥18 years of age.
* Patients who have received at least one prior line of standard of care therapy.
* Patients able to…
Inclusion Criteria:
* Patients with recurrent/refractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)
* -OR- Patients with recurrent/refractory cancer ≥18 years of age.
* Patients who have received at least one prior line of standard of care therapy.
* Patients able to provide treatment and outcome information from previous line(s) of therapy.
* Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.
* Patients who are scheduled for or have recently undergone a tumor biopsy, excision, or resection.
* Patients willing to have a blood draw or buccal swab performed for matched normal material for comparison during tumor DNA profiling.
Exclusion Criteria:
* Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and/or genetic profiling, defined as \<0.3g for resections or core/fine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.
* Patients with insufficient health indicators to undergo therapeutic intervention.
Contacts
No contact information available.
What are you hoping to find?
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.